Keywords: Pfizer, Post-marketing studies, Chantix, Pristiq, Toviaz, Smoling cessation, Major depressive disorders, Urinary incontinence

Research results for Pfizer's Chantix, Pristiq and Toviaz

Article | 27 January 2013

Print This

Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating to three already ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in